Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

18.42
+0.87004.96%
Pre-market: 18.13-0.2900-1.57%05:37 EDT
Volume:7.07M
Turnover:130.69M
Market Cap:14.69B
PE:-16.48
High:18.83
Open:18.07
Low:17.97
Close:17.55
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:1.28
T/O Rate:4.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:23.33
PE(LYR):-12.76

Loading ...

Summit Therapeutics falls -27.4%

TIPRANKS
·
May 01

Goldman Sachs Remains a Buy on Summit Therapeutics (SMMT)

TIPRANKS
·
May 01

Summit Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 01

Summit Therapeutics Q1 FY26 net loss widens to $189.4 million; operating expenses rise to $195.2 million

Reuters
·
May 01

Summit Therapeutics Q1 adjusted loss narrows despite higher R&D costs

Reuters
·
May 01

Summit Therapeutics Q1 Adjusted EPS USD -0.15 VS. Ibes Estimate USD -0.18

THOMSON REUTERS
·
May 01

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026

THOMSON REUTERS
·
May 01

Electric Vehicle Adoption Reaches 'Tipping Point' Globally, Trend Deemed Self-Sustaining

Deep News
·
Apr 26

Summit Therapeutics put volume heavy and directionally bearish

TIPRANKS
·
Apr 23

Summit partner selection for ASCO plenary signals strong OS, says Leerink

TIPRANKS
·
Apr 22

Summit partner selection for ASCO ‘likely a major positive,’ says Guggenheim

TIPRANKS
·
Apr 22

IonQ, Oklo, And Robinhood Are Among the Top 10 Large-Cap Gainers Last Week (April 13-April 17): Are the Others in Your Portfolio?

Benzinga_recent_news
·
Apr 19

Evercore ISI Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)

TIPRANKS
·
Apr 17

Summit Therapeutics Inc Stock (SMMT) Moved Up by 12.03% on Apr 16: Drivers Behind the Movement

TradingKey
·
Apr 17

Summit Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Price Target $45

THOMSON REUTERS
·
Apr 08

Summit Therapeutics initiated with a Buy at Stifel

TIPRANKS
·
Apr 08

Wells Fargo Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)

TIPRANKS
·
Apr 02

Barclays Remains a Hold on Summit Therapeutics (SMMT)

TIPRANKS
·
Mar 30

Summit Therapeutics Links Ivonescimab Brain Metastases Data To November PDUFA

Simply Wall St.
·
Mar 29

Summit Therapeutics presents HARMONi intracranial efficacy findings for ivonescimab plus chemotherapy in EGFR-mutated NSCLC; intracranial PFS HR narrows to 0.53 in patients with baseline brain metastases

Reuters
·
Mar 28